Additional file 1: of Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program

Heidenreich, Axel; Gillessen, Silke; Heinrich, Daniel; Keizman, Daniel; OâSullivan, Joe; Carles, Joan; Wirth, Manfred; Miller, Kurt; Reeves, John; Seger, Monica; Nilsson, Sten; Saad, Fred

doi:10.6084/m9.figshare.7552409.v1

12885_2018_5203_MOESM1_ESM.docx (30 kB)

Additional file 1: of Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program

journal contribution

posted on 2019-01-07, 05:00 authored by Axel Heidenreich, Silke Gillessen, Daniel Heinrich, Daniel Keizman, Joe OâSullivan, Joan Carles, Manfred Wirth, Kurt Miller, John Reeves, Monica Seger, Sten Nilsson, Fred Saad

Table S1. Patient disposition according to symptom status. (DOCX 30 kb)

Funding

Pharmaceutical Division of Bayer

History

Usage metrics

Keywords

Radium-223 mCRPC, asymptomatic Symptomatic Bone metastases

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Additional file 1: of Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program

Funding

Pharmaceutical Division of Bayer

History

Usage metrics

Categories

Keywords

Licence

Exports